Overview Metabolic
syndrome is a cluster of cardiovascular risk factors that is said to affect 47
million Americans. The syndrome is characterized by abdominal obesity, atherogenic
dyslipidemia, elevated blood pressure, insulin resistance, and prothrombotic and
pro-inflammatory states. Accurate diagnosis and aggressive treatment of this syndrome,
which includes lifestyle changes and pharmacologic interventions, are important
to the health of all patients, especially those with a diagnosis of type II diabetes.
In this Web Workshop, Frances M. Sahebzamani, PhD, ARNP, discusses the
root causes of the metabolic syndrome and will use a case study approach to demonstrate
how effective lifestyle changes and pharmacologic interventions can be used to
treat diabetic patients with metabolic syndrome. Learning
Objectives Upon completion of this course,
you should be able to: - Describe the ATP III criteria
that make up the metabolic syndrome
- Describe lifestyle
changes that can improve outcomes for diabetic patients with metabolic syndrome
- List pharmacologic interventions that have been shown
to improve outcomes for diabetic patients with metabolic syndrome
Learner
Participation to Earn Credit To earn a CE certificate,
you must: Computer
Requirements to Participate Click
here to view the computer requirements to participate in this activity. Target
Audience This CE activity is designed to meet the learning
needs of nurse practitioners as well as other healthcare providers who care for
patients with dyslipidemia and related disorders. |
Faculty and Disclosures
 Alan P. Agins, PhD
[BioSketch]
Adjunct Associate Professor,
Brown University Medical School, Providence,
RI;
Adjunct Assistant Professor, Pennsylvania State University School of Nursing, University Park,
Pa; President, PRN Associates, Ltd.
Disclosure: Speaker’s
Bureau: Forest Laboratories and Sepracor,
Inc.; Consultant: Pharmavite.
 Frances
M. Sahebzamani, PhD, ARNP [BioSketch]
Assistant Professor, Assistant Director of Research, Department
of Family Medicine; Co-Director, USF Prediabetes Treatment and Research Center,
University of South Florida, Tampa, Florida
Disclosure: Advisory Board:
Eli Lilly, Merck; Presenter: Pfizer, AstraZeneca.
| | |
Accreditation Statement Continuing
Education for Nurse Practitioners
This program has been granted 1 contact hour of continuing education (which includes
0.2 hours of pharmacology) by the American Academy of Nurse Practitioners, course
number 0311385. 
Accreditation
Period
This program was initially published
on March 18, 2004, and is eligible for credit through February 20, 2007. | |
| Course
Fees This course is FREE
to all healthcare professionals. | | | |
|
